Johnson & Johnson Signs Communiqué on Expanded Global Access for COVID-19

October 9, 2020

Johnson & Johnson recently announced that it’s joined 15 other companies in signing a Communiquie on Expanded Global Access to ensure that people everywhere – regardless of their income level – have access to COVID-19 vaccines, therapeutics and diagnostics under development at these companies. 

Each of the signing companies—AstraZeneca; Bayer; bioMérieux; Boehringer Ingelheim; Bristol Myers Squibb; Eisai; Eli Lilly; Gilead; GSK; Johnson & Johnson; Merck & Co. (known as MSD outside the U.S. and Canada); Merck KGaA, Darmstadt, Germany; Novartis; Pfizer; Roche; and Sanofi—have agreed to follow a specific set of five principles outlined in the communiqué. The agreement calls on governments, NGOs and other stakeholders to join the cause and help accelerate the end of the pandemic.

As part of its commitment today, Johnson & Johnson also plans to allocate up to 500 million vaccine doses to lower income countries with delivery beginning mid next year.

“Johnson & Johnson stands alongside our peers and the Bill & Melinda Gates Foundation in our unwavering commitment to equitable global access to the medicines and innovations being developed to fight the COVID-19 pandemic,” says Alex Gorsky, Chairman and CEO, Johnson & Johnson.”

“BioUtah continues to applaud J&J’s commitment to the integrity of science in vaccine development and ensuring access to COVID-19 medicines worldwide,” said Kelvyn Cullimore, president and CEO of BioUtah.